Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2025 | Epcoritamab in combination with R-CHOP or lenalidomide for Richter’s transformation

Arnon Kater • 6 Dec 2025
ASH 2025
Chronic Lymphocytic Leukemia Leukemia Antibodies Epcoritamab Lenalidomide R-CHOP

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses outcomes of epcoritamab combined with R-CHOP or lenalidomide for the treatment of Richter’s transformation. Prof. Kater highlights that epcoritamab montherapy demonstrates efficacy, but also has potential in combination with classical therapies such as chemotherapy or immunomodulators. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arnon Kater

Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1 1:48
Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1
Arnon Kater • 6 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease 19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status 2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
Overcoming T-cell dysfunction 1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023

Related Videos

A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML 3:16
A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML
Uday Popat • 8 Dec 2025
AutoSCT versus consolidation chemotherapy as post-remission treatment in newly diagnosed AML 2:19
AutoSCT versus consolidation chemotherapy as post-remission treatment in newly diagnosed AML
Dimitrios Kotsos • 6 Dec 2025
Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML 2:48
Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML
Anand Patel • 25 Nov 2025
Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1 1:48
Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1
Arnon Kater • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals